 Connection
Douglas Kemme to Humans
This is a "connection" page, showing publications Douglas Kemme has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.015 |
|
|
|
-
Kessler ER, Callihan E, Hu J, Eule C, Srivastava G, Kemme DJ, Iruku P, Rana V, Moore J, Schuster SR, Amirault M, Flaig TW, Lam ET. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma. Cancer Res Commun. 2023 06; 3(6):1004-1012.
Score: 0.005
-
Browning ET, Huckleberry JM, Barrow WB, Restauri NL, Kemme DJ, Cool CD, Weyant MJ, Franklin WA, Camidge DR. Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity. J Clin Oncol. 2016 Jan 10; 34(2):e6-8.
Score: 0.003
-
Kemme DJ, Daniel CI. Aminoglycoside dosing: a randomized prospective study. South Med J. 1993 Jan; 86(1):46-51.
Score: 0.002
-
Kemme DJ, Bunn PA. State of the art therapy of mycosis fungoides and Sézary syndrome. Oncology (Williston Park). 1992 Feb; 6(2):31-42; discussion 44, 47-8.
Score: 0.002
-
Kemme DJ, Rainer WG. Subendocardial arteriovenous malformation in a patient with unstable angina. Clin Cardiol. 1991 Jan; 14(1):82-4.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|